CompletedNCT00068146
Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) to Evaluate Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-associated Lymphoma
Studying Autoimmune lymphoproliferative syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- V. Koneti Rao, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Enrollment
- 77 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2002 – 2012
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00068146 on ClinicalTrials.govOther trials for Autoimmune lymphoproliferative syndrome
Additional recruiting or active studies for the same condition.
See all trials for Autoimmune lymphoproliferative syndrome →